Abstract 563P
Background
Around 1.9 million new cancer cases and around 930,000 deaths were attributed to colorectal cancer (CRC) worldwide in 2020. The European Union recommends population-based CRC screening. Reported long‘term results from various CRC screening programs are quite controversial as some of them report no survival gains. In June 2009 the CRC screening program was initiated in Lithuania. The aim of the study is to report the impact of CRC screening program on long-term mortality.
Methods
The anonymous data of the population aged 50-74 from the years 2013 to 2019, who participated in the CRC screening program were extracted from the statistical database of the National Health Insurance Fund, which provided both, the participation in different services of screening indicated by specific codes, and the mortality and survival marked in the database. For statistical analysis we divided patients in three groups: Negative fecal immunochemical test (FIT); positive FIT and screening colonoscopy performed; positive FIT and screening colonoscopy was not performed. The statistical analysis was performed using the R statistical software package v4.2.2.
Results
From the year 2013 to 2019 a total of 1,521551 people participated in the screening program. During the observation period 66920 (4.4%) patients died. The highest mortality was seen in patients that were diagnosed with cancer (19%). High mortality was seen in patients that did not proceed with further colonoscopy after a positive FIT. These patients had a significantly higher mortality rate: Negative FIT (4.2%) vs. Positive FIT + colonoscopy (4.9%) vs. Positive FIT - colonoscopy (8.6%); p<0.001. A univariate logistic regression analysis revealed that positive FIT + colonoscopy (OR 1.19 95% CI 1.15-1.24; p<0.001) and positive FIT - colonoscopy (OR 2.18 95% CI 2.12-2.24; p<0.001) groups had significantly increased mortality risks when compared to the negative FIT group.
Conclusions
Fully completed screening after a positive FIT result is associated with significantly reduced mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10